View Cart  

OIG: HHS Must Clamp Down on Off-Label Drug Promotion

Drugmakers could see a more forceful crackdown on off-label promotion, says a new Office of Inspector General (OIG) report that directs HHS to focus on the practice.

To View This Article:


Subscribe To The Executive Briefing Series

Buy This Article Now

Add this article to your cart for $40.00